retatrutide legal status europe UK 2026: Phase 3 Results Retatrutide for weight loss: Study

This is especially common in patients using GLP-1 medications, which are prescribed to aid weight reduction

[DOI] [PubMed] [Google Scholar] 217.Qualmann C., Nauck M.A., Holst J.J., Orskov C., Creutzfeldt W

In SURMOUNT-1 the 15 mg arm averaged 22.5% body weight loss at 72 weeks, only modestly higher than the 10 mg arm at 21.4%

Contribution statement All authors contributed to the conception and design of this review, drafting of the article, revising for critically important content and approved the final version to be published

GLP-1 receptor agonists have demonstrated anti-inflammatory and neuroprotective effects across a range of neurological and psychiatric conditions

Briefly, sygl-1 cDNA encoding full-length SYGL-1 (a.a